Abstract

Tissue engineered vascular substitutes have the potential to be used for treatment of clinically advanced atherosclerotic disease. Design considerations for a tissue engineered vascular substitutes include physiologic levels of flow, low thrombogenicity, and adaptation to changes in flow demands. Some of these attributes may be evaluated using less expensive bench top methods before proceeding to in vivo testing. We have recently developed several methods for determining flow, thrombogenicity, and adaptation in tissue engineered arteries.

This content is only available via PDF.